# Labviva

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/labviva

- Industry: Software
- Headquarters: Boston, US
- Website: www.labviva.com
- Total disclosed funding: $53M
- Latest round: Series B (Jan 13, 2025)
- Investors on record: 5

## About

Labviva, Inc. is a US-based company that specializes in developing integrated platforms for the life sciences sector, focusing on enhancing procurement and inventory management processes for researchers and scientists.Founded in 2017 and headquartered in Boston, US, Labviva, Inc. focuses on providing innovative solutions for the life sciences industry. The company was established by Aaron Miramontes, Nicholas Rioux, and Siamak Baharloo, who also serves as the CEO. Labviva has successfully raised USD 25.00 mn in its Series B funding round, led by 53 Stations, with participation from investors including BioSpring Partners and B Capital Group. With a total of 5 deals, the company’s latest funding round occurred on January 13, 2025, bringing the total amount raised to USD 25.00 mn and a current company valuation of USD 116.83 mn.Labviva provides an integrated platform tailored for the life sciences sector, emphasizing procurement and inventory management. Their main offerings include the Labviva Purchasing Platform, which connects users with various suppliers for laboratory products, and the Labviva Inventory Management System, designed to automate stock control and compliance tracking. The company primarily serves biopharma businesses, academic institutions, and research organizations across North America and Europe, streamlining their procurement processes and operational efficiency.Labviva operates on a subscription-based revenue model, generating income through partnerships with suppliers and access fees charged to research institutions. Clients benefit from the Labviva Purchasing Platform and Inventory Management System under diverse pricing structures, including annual subscriptions and transaction fees. This model aligns with the growing demand for automated solutions in the life sciences sector, allowing clients to optimize supply chains and reduce R&D costs.In January 2025, Labviva, Inc. secured USD 25.00 mn in Series B funding to enhance its product development, marketing efforts, and customer support. The company plans to expand its reach into international markets, leveraging the recent funding to capitalize on growth opportunities. This strategic move is aimed at accelerating new product launches and increasing the company's footprint in the life sciences sector.

## Funding rounds

- Series B, Jan 13, 2025, $25M — B Capital, Glasswing Ventures, BioSpring, 53 Stations
- Series A, Mar 27, 2023, $20M — B Capital, Glasswing Ventures, Senator Investment Group, BioSpring
- Seed, Jun 21, 2021, $8M — B Capital, Glasswing Ventures, Senator Investment Group

## Investors

- B Capital (https://capitalatlas.ai/funds/b-capital) — Seed, Series A, Series B
- Glasswing Ventures (https://capitalatlas.ai/funds/glasswing-ventures) — Seed, Series A, Series B
- Senator Investment Group (https://capitalatlas.ai/funds/senator-investment-group) — Seed, Series A
- BioSpring (https://capitalatlas.ai/funds/biospring) — Series A, Series B
- 53 Stations (https://capitalatlas.ai/funds/53-stations) — Series B